Scholarly record
CLINICAL IMPLICATIONS OF ALPHA TNF LEVELS IN RHEUMATOID ARTHRITIS
Abstract
Introduction. Rheumatoid arthritis is a chronic inflammatory disease with progressive erosive joint damage. The sometimes reduced effectiveness of conventional immunosuppressive treatments, their multiple adverse effects, and the overall difficulty in managing sinusoidal clinical panel (with critical periods or “peaks” and intercritical periods with varying degrees of activity) motivated the search for therapeutic alternatives for controlling the underlying disease. Material and methods. This is a prospective observational study on patients with rheumatoid arthritis receiving anti-TNF alpha biologic therapy found by two rheumatologist investigators during 3 years. From this group we selected those patients receiving anti-TNF? biological therapy. A study group of 15 patients was followed, as well as a control batch of 6 patients with the same diagnosis. In our study the individual TNF alpha level was determined by chemiluminescence detection by immunochemical method. Clinical data included the presence and quantification of painful and swollen joints, the presence of morning stiffness, and the functional scores of patients. Results and discussions. The study group (15 patients) consists of 14 women (93.3%) and one male. Comparisons of the mean values of TNF alpha between the subgroups presenting joint pain and the non-pain subgroup reveals a statistically significant difference in favor of the pain subgroup (514.47 vs 218.34), p = 0.016. We observed shows a net difference of TNF alpha levels in favor of those with arthritis (577.67 vs 375.28), but without a significant statistical correlation (p = 0.876). Conclusions. The data collected so far in our study shows a strong correlation between subjective parameters (like the joint pain) and the level of TNF alpha, indicating a weak control of the disease clinically, in the context of an insufficiently inhibited level of TNF alpha in the patient's serum.
Publication Impact Profile
Publication details
References4
MA X, XU S. TNF inhibitor therapy for rheumatoid arthritis. Biomedical Reports. 2013;1(2):177-184. DOI: 10.3892/br.2012.42.
Fox DA. Cytokine blockade as a new strategy to treat rheumatoid arthritis; Inhibition of tumor necrosis factor, Arch Intern Med 2000; 160:437-44
Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975256495–497
Lineker S, Badley E, Charles C, Hart L, Streiner D. Defining morning stiffness in rheumatoid arthritis. J Rheumatol. 1999 May; 26 (5): 1052-7
View or Download full articleAccess options
SWS access login
Login as SWS Scientific CommitteeLogin as SWS Scientific PartnerLogin as SWS AuthorAuthors and approved SWS contributors will read and export their own linked papers after identity matching by SWS profile, email and SGEM GlobalID.
For librarian assistance: [email protected]
Purchase Instant Access
- Article can be downloaded after successful payment.
- Article may be used according to SWS library access terms.
- Article cannot be redistributed.
